Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and-independent mechanisms

Oncogene

Volumn 30, Issue 33, 2011, Pages 3612-3624

  Bug, M ^a   Dobbelstein, M ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

anthracyclines; doxorubicin; E2F1; idarubicin; p53; WRAP53

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; WRAP53 PROTEIN;

ARTICLE; CANCER CELL; CELL NUCLEUS; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; EXON; GENE EXPRESSION; GENOTOXICITY; MESSENGER RNA SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTHRACYCLINES; CELLS, CULTURED; DISEASE PROGRESSION; DOXORUBICIN; E2F1 TRANSCRIPTION FACTOR; GENES, P53; HUMANS; MUTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; TELOMERASE; TOPOISOMERASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051795657     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.72     Document Type: Article

References (51)

1. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. (2009). A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137: 87-98.
2. Blandino G, Levine AJ, Oren M. (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485. (Pubitemid 29060623)
3. Bode AM, Dong Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805. (Pubitemid 39331151)
4. Bush JA, Li G. (2002). Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 98: 323-330. (Pubitemid 34188673)
5. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K et al. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679. (Pubitemid 28435584)
6. Capranico G, Butelli E, Zunino F. (1995). Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res 55: 312-317.
7. Capranico G, Zunino F, Kohn KW, Pommier Y. (1990). Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxi-city. Biochemistry 29: 562-569. (Pubitemid 20037665)
8. Cashman DJ, Kellogg GE. (2004). A computational model for anthracycline binding to DNA: tuning groove-binding intercalators for specific sequences. J Med Chem 47: 1360-1374. (Pubitemid 38327464)
9. Collins I, Weber A, Levens D. (2001). Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol 21: 8437-8451. (Pubitemid 33108603)
10. Corbett AH, Hong D, Osheroff N. (1993). Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. J Biol Chem 268: 14394-14398. (Pubitemid 23195567)
11. Crampton N, Bonass WA, Kirkham J, Rivetti C, Thomson NH. (2006). Collision events between RNA polymerases in convergent transcription studied by atomic force microscopy. Nucleic Acids Res 34: 5416-5425. (Pubitemid 44742431)
12. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202. (Pubitemid 44311070)
13. Dumaz N, Meek DW. (1999). Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 18: 7002-7010. (Pubitemid 30000453)
14. Hargrave RM, Davey MW, Davey RA, Kidman AD. (1995). Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anticancer Drugs 6: 432-437.
15. Heinlein C, Krepulat F, Lohler J, Speidel D, Deppert W, Tolstonog GV. (2008). Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 122: 1701-1709. (Pubitemid 351413415)
16. Hershko T, Ginsberg D. (2004). Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 279: 8627-8634. (Pubitemid 38295917)
17. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W et al. (2000). Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645-648.
18. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al. (2002). MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21: 6236-6245. (Pubitemid 35415340)
19. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK et al. (2006). A topoisomerase II beta-mediated dsDNA break required for regulated transcription. Science 312: 1798-1802. (Pubitemid 43962898)
20. Kurz EU, Douglas P, Lees-Miller SP. (2004). Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 279: 53272-53281. (Pubitemid 40051831)
21. Lai EC. (2002). Micro RNAs are complementary to 30 UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363-364.
22. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872. (Pubitemid 40017691)
23. Lavorgna G, Dahary D, Lehner B, Sorek R, Sanderson CM, Casari G. (2004). In search of antisense. Trends Biochem Sci 29: 88-94. (Pubitemid 38186579)
24. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK et al. (2000). High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97: 4174-4179. (Pubitemid 30226106)
25. Liu H, Lu ZG, Miki Y, Yoshida K. (2007). Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol 27: 8480-8491.
26. Liu H, Hew HC, Lu ZG, Yamaguchi T, Miki Y, Yoshida K. (2009). DNA damage signalling recruits RREB-1 to the p53 tumour suppressor promoter. Biochem J 422: 543-551.
27. Lotfi K, Zackrisson AL, Peterson C. (2002). Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett 178: 141-149. (Pubitemid 34178538)
28. Lozano G. (2007). The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 17: 66-70. (Pubitemid 46109293)
29. Mahmoudi S, Henriksson S, Corcoran M, Mendez-Vidal C, Wiman KG, Farnebo M. (2009). Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 33: 462-471.
30. Mahmoudi S, Henriksson S, Weibrecht I, Smith S, Soderberg O, Stromblad S et al. (2010). WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies. PLoS Biol 8: e1000521.
31. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47-54. (Pubitemid 30257035)
32. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A et al. (2006). TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 34: D108-D110.
33. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229. (Pubitemid 38720829)
34. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
35. Nitiss JL. (2009). DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9: 327-337.
36. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L et al. (2003). Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5: 552-558. (Pubitemid 36781090)
37. Prescott EM, Proudfoot NJ. (2002). Transcriptional collision between convergent genes in budding yeast. Proc Natl Acad Sci USA 99: 8796-8801. (Pubitemid 34693638)
38. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E et al. (2000). Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405: 974-978. (Pubitemid 30435057)
39. Robinson MJ, Corbett AH, Osheroff N. (1993). Effects of topoisome-rase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry 32: 3638-3643. (Pubitemid 23126939)
40. Stiewe T, Putzer BM. (2000). Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26: 464-469.
41. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. (2007). Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212-2219. (Pubitemid 46536646)
42. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L et al. (2000). Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275: 29503-29512. (Pubitemid 32043826)
43. Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z. (2007). Induction of ATM activation, histone H2AX phosphory-lation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle 6: 371-376.
44. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. (2008). The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22: 1337-1344. (Pubitemid 351717524)
45. Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG et al. (2003). Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 34: 157-165. (Pubitemid 36666926)
46. Urist M, Tanaka T, Poyurovsky MV, Prives C. (2004). p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18: 3041-3054. (Pubitemid 39658173)
47. Van Hille B, Perrin D, Hill BT. (1999). Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIalpha and IIbeta isoforms. Anticancer Drugs 10: 551-560. (Pubitemid 29410802)
48. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y et al. (2006). Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8: 1025-1031. (Pubitemid 44314735)
49. Wang S, El-Deiry WS. (2006). p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 66: 6982-6989. (Pubitemid 44197673)
50. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH et al. (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11: 694-704.
51. Wutz A, Smrzka OW, Schweifer N, Schellander K, Wagner EF, Barlow DP. (1997). Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 389: 745-749. (Pubitemid 27458963)